comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-10 08:21:21 - browse：17

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Alzheimer's risk factor APOE4 may be a distinct form of the disease

entertainment

leisure time

WSS

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

U.K. decision on ALS drug has neurologists, advocates up in arms

Caitlin Bernard's story shows physicians can't shy from advocacy

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

New rules on organ donation and transplantation 'will bring chaos'

Russian special forces kill a gunman who broke into a private house near Moscow

hotspot

comprehensive

entertainment

Walensky prepares to leave CDC — and Congress — behind

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Duchenne breakthrough therapy leaves behind pioneering families

Pancreatic cancer is often deadly, but new discoveries are raising hope

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Review: 'Barbie' will hit you like a shot in the heart

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Hollywood unions extend contract negotiations for actors

Providers still hesitate to prescribe buprenorphine, study finds

leisure time

Oral obesity drug from Viking Therapeutics hits key early target

Pancreatic cancer is often deadly, but new discoveries are raising hope

Bird flu in dairy cattle: New measures to control spread to humans

Russian special forces kill a gunman who broke into a private house near Moscow

FDA official pushes for dedicated emerging pathogens team

Hundreds died while taking an arthritis drug, but nobody alerted patients

entertainment

leisure time

entertainment

Wikipedia